A board governance framework for evaluating CMC, Manufacturing & Quality (CMCQ) leadership in biopharma. Eight years to write, drawing on 120+ commercial product launches — the collective careers of seventeen CxO-level technical operations leaders who have led CMCQ at world-leading Fortune 100, mid-cap, and startup biotech. It replaces the question "is the CTO good?" with the more precise one: "is our CMC leadership calibrated to the risk most likely to end our next capital event?"
Already downloaded by 300+ CMC, Quality & Tech Ops leaders across 200+ biopharma companies.
Technical risk in biopharma rarely announces itself early. It is repriced later — by the FDA, an acquirer, the IPO market, or the next financing round. This framework helps boards identify and govern that risk before the capital event does.
Across 10,954 drug development programs (2014–2023), the probability of reaching approval from Phase I has declined to roughly 6.7%. As clinical probabilities tighten, operational execution becomes a larger determinant of enterprise value — and boards systematically misprice it.
The most commonly cited approval-blocking deficiencies are not clinical. They are manufacturing and CMC. The FDA's July 2025 release of 202 Complete Response Letters confirmed that 74% cited quality or manufacturing deficiencies — up from roughly 15% two decades earlier. (CRLs are typically multi-causal; this is the share that cite quality or manufacturing as a factor.)
A preventable manufacturing CRL has triggered single-day valuation declines in the 33–34% range. The difference from a clinical failure is decisive: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
Manufacturing CRLs triggered 33–34% single-day valuation declines. Clinical failures triggered 50–75%. The difference: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
The companies below are illustrative examples, not a statistical distribution. The load-bearing evidence is the population-level finding above — 74% of the FDA's 202 published CRLs cited quality or manufacturing.
| Company | Year | Valuation impact | CRL type |
|---|---|---|---|
| Fortress Biotech | 2025 | −33.7% | CMC / Mfg |
| Alvotech | 2025–26 | −34% | CMC / Mfg |
| Immunomedics | 2019–20 | Delayed | CMC / Mfg |
| Applied Therapeutics | 2024 | −75% | Clinical |
| Corcept Therapeutics | 2025 | −50% | Clinical |
CMC performance is not fixed "technical strength." It is a stage-specific risk function with five simultaneous dimensions. At any given stage, one mandate is dominant — its failure is most likely to be fatal to the current capital event — but the others remain active. The correct mental model is a radar chart, not a checklist.
At each stage one mandate dominates — the failure most likely to end the current capital event — while the others stay active. Watch the shape rotate from Possible (pre-IND) through to Durable (commercial). The right hire is calibrated to the dominant mandate now, and ready for the one next.
Make a product possible. Translation into an investable, regulator-legible development position.
Make it reproducible. Systems replace heroics. CMC, assay, and process control are institutionalized.
Make it diligence-survivable. Documentation integrity, auditability, and narrative stability under scrutiny.
Build the operational machine. The platform becomes a multi-program operating system.
Harden enterprise performance under stress. Inspections, shortages, geopolitics, redundancy.
These weightings are directional, not predictive — the CTO Mandate Framework is a practitioner-consensus model, built and pressure-tested by senior operators rather than peer-reviewed research. The value lies in the conversation they structure. The full framework maps dominant, rising, and maintenance mandates across all five stages, with a board calibration tool that surfaces where directors disagree about what the role requires.
Three roles boards routinely conflate. They own different risks — and each is the priority hire at a different moment.
| Role | What they own | The risk they retire | Priority hire when… |
|---|---|---|---|
| Chief Technology Officer (CTO) | Whole CMC and technical strategy across the lifecycle | The therapy cannot be made, scaled, or defended to a regulator | Series A in cell & gene therapy; Series B+ / Phase 2a in other modalities — through pre-IPO calibration and M&A readiness |
| VP/SVP Technical Operations | Converting R&D process to product, CDMO selection, day-to-day manufacturing, tech transfer, and supply | A process that will not reproduce at commercial volume | Series A, through clinical-to-commercial supply; succeeded by a CTO approaching launch or multi-asset build-out |
| VP Quality / CQO | Quality systems, compliance, and inspection readiness | A quality system that buckles at inspection or at scale | Series B / Phase 2 — ahead of pre-approval inspection, or after a quality signal |
Cell & gene therapy is CMC-intensive from the outset — these companies typically need a CTO by Series A, where other modalities can begin with a VP/SVP Technical Operations at Series A and elevate to a CTO at Series B, or as they approach launch or build out a multi-asset portfolio.
A voting director with hands-on CMC operating experience — not a scientific advisor. A fiduciary who has managed CAPA systems, led pre-approval inspections, and negotiated CMC deficiency responses with the FDA, and who can distinguish a manageable deviation trend from a systemic quality-culture failure in real time.
If you do not have a CMC board member, you need a CTO who can translate operational risk into language directors and investors understand — and create an unfiltered information channel so the board learns about manufacturing risk before it becomes a CRL. The most undervalued CTO capability in biopharma.
Does your CTO have the authority that matches your dominant mandate?
Downloaded by 300+ senior CMC, Quality and Technical Operations leaders — CxOs, VPs and function heads — across 200+ biopharma companies, and read at board and investor level.
A representative sample of organizations whose teams downloaded the framework. We never share individual details.
Shaped by the collective careers of seventeen CxO-level technical operations leaders who have run CMC, Manufacturing and Quality at world-leading Fortune 100, mid-cap, and startup biotech — more than 120 commercial product launches and over 500 collective years running CMC, Manufacturing and Quality between them. This is not one operator's opinion; it is the institutional memory of the people who have actually shipped medicine, organized into a single governance model.
The seventeen operators who reviewed and pressure-tested the framework — seven hold PhDs. Each links to LinkedIn.
The complete governance matrix, the Board Calibration Tool, and the operational KPI sets.
If you would like to discuss how this applies to your board, your CTO mandate, or your next technical leadership hire, we welcome the conversation.